Inventor
DURRANT LINDA GILLIAN
GB13 patents
⚠️ This page may combine multiple inventors who share the name “DURRANT LINDA GILLIAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCANCELL LTD
8 patentsUS7267821B2Sep 11, 2007
Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer
SCANCELL LTD9 citations70
US10233220B2Mar 19, 2019
Anti-tumour response to modified self-epitopes
SCANCELL LTD4 citations67
US12552876B2Feb 17, 2026
Anti-fucosyl-GM1 antibodies
SCANCELL LTD0 citations60
US12258377B2Mar 25, 2025
Anti-tumour response to modified self-epitopes
SCANCELL LTD0 citations56
US12458688B2Nov 4, 2025
Epitopes
SCANCELL LTD0 citations55
US11382985B2Jul 12, 2022
Anti-tumour immune responses to modified self-epitopes
SCANCELL LTD0 citations54
US10695438B2Jun 30, 2020
Anti-tumour immune responses to modified self-epitopes
SCANCELL LTD1 citations54
US12595313B2Apr 7, 2026
Modified Fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
SCANCELL LTD0 citations52
CEPHALON AUSTRALIA PTY LTD
2 patentsUS7915387B2Mar 29, 2011
Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
CEPHALON AUSTRALIA PTY LTD11 citations80
US8343490B2Jan 1, 2013
Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
CEPHALON AUSTRALIA PTY LTD0 citations48
DURRANT LINDA GILLIAN
2 patentsUS8742088B2Jun 3, 2014
Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responses
DURRANT LINDA GILLIAN4 citations61
US8187600B2May 29, 2012
Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses
DURRANT LINDA GILLIAN1 citations41